Aspects and Implementation of Pharmaceutical Quality by Design

Tamás Sovány,Katalin Kristó,Ildikó Csóka

DOI: https://doi.org/10.3390/pharmaceutics16060832

IF: 6.525

2024-06-19

Pharmaceutics

Abstract:The introduction of the Quality by Design concept in 2004 has brought a paradigm shift in the pharmaceutical industry as well as a new era in pharmaceutical research and development [...]

pharmacology & pharmacy

What problem does this paper attempt to address?

Quality-by-design in pharmaceutical development: From current perspectives to practical applications

Béla Kovács,Orsolya Péterfi,Boglárka Kovács-Deák,István Székely-Szentmiklósi,Ibolya Fülöp,László-István Bába,Francisc Boda

DOI: https://doi.org/10.2478/acph-2021-0039

IF: 3.2993

2021-04-03

Acta Pharmaceutica

Abstract:Abstract Current pharmaceutical research directions tend to follow a systematic approach in the field of applied research and development. The concept of quality-by-design (QbD) has been the focus of the current progress of pharmaceutical sciences. It is based on, but not limited, to risk assessment, design of experiments and other computational methods and process analytical technology. These tools offer a well-organized methodology, both to identify and analyse the hazards that should be handled as critical, and are therefore applicable in the control strategy. Once implemented, the QbD approach will augment the comprehension of experts concerning the developed analytical technique or manufacturing process. The main activities are oriented towards the identification of the quality target product profiles, along with the critical quality attributes, the risk management of these and their analysis through in silico aided methods. This review aims to offer an overview of the current standpoints and general applications of QbD methods in pharmaceutical development.

pharmacology & pharmacy
Quality by Design (QbD) in pharmaceutical development: A comprehensive review

Pratik B. Aru,Mayur S. Gulhane,Vinayak A. Katekar,Swati P. Deshmukh

DOI: https://doi.org/10.30574/gscbps.2024.26.1.0019

2024-01-30

GSC Biological and Pharmaceutical Sciences

Abstract:Quality by Design (QBD) represents a transformative approach to pharmaceutical development, emphasizing a systematic and science-driven methodology to ensure consistent product quality. This article explores various facets of QBD, ranging from its foundational principles to challenges, opportunities, and future perspectives. The journey begins with an introduction to QBD, outlining its key concepts and objectives. The article then delves into the key principles of QBD, such as the establishment of a design space and the importance of risk assessment. Real-time Release Testing (RTRT) is discussed as a critical element in ensuring product quality and consistency. Case studies are presented, showcasing successful implementations of QBD in drug development and highlighting their impact on product quality and regulatory compliance. The regulatory landscape is examined, focusing on expectations and requirements related to QBD, as well as the integration of QBD concepts into regulatory submissions. Challenges and opportunities associated with QBD implementation are thoroughly explored, addressing industry-wide adoption challenges and strategies to overcome resistance to change. Continuous improvement emerges as a central theme, with a focus on its role in refining processes, learning from experiences, and fostering a culture of innovation. The article then looks towards the future, discussing the integration of advanced technologies, including analytical tools and Industry 4.0, and their implications for QBD. Global harmonization efforts are examined, emphasizing collaborative initiatives and their impact on aligning regulatory expectations globally.
Quality By Design (QbD): A Comprehensive Understanding and Implementation In Pharmaceuticals Development

Sarita S. Pawar,Yash S. Mahale,Prachi A. Kalamkar,Rohini A. Satdive,Sujata K. Sonawane,Sneha P. Bhapkar

DOI: https://doi.org/10.2174/1573412919666230914103355

2023-09-14

Current Pharmaceutical Analysis

Abstract:Abstract: Quality by Design (QbD) is a systematic approach for improvement that stresses product and process and begins with a predetermined objective, as recommended by the USFDA and International Council Harmonization (ICH). Regulatory bodies frequently highlight the use of ICH quality criteria, which include Q8, Q9, Q10, and Q11. The differentiation between the traditional and QbD helps to study the risk assessment and technique for developing new products. There are a few steps involved in pharmaceutical and Analytical QbD. Various factors were used for the study of QbD, such as Analytical Target Product Profile (ATPP), Risk Assessment Quality Design Space, Control Strategy, etc. Critical Quality Attribute (CQA) may be understood and analyzed via a way of means of understanding the goods and technique and risk evaluation is useful for effective verbal exchange among FDA and industry, research/improvement and production, and amongst a couple of production sites inside the company. Life-cycle management of analytical procedure begins off evolving with the establishment of ATP and maintains until the approach is in use. The design of the experiment (DoE) involves the Q8 guidelines. DoE has been used in the rational development and optimization of analytical methods. Culture media composition, mobile phase composition, flow rate, and time of incubation are input factors (independent variables) that may be screened and optimized using DoE. Process analytical technology is implemented for the understanding and identification of developing a product and techniques. There are various benefits and applications of QbD in the pharmaceutical industry.

pharmacology & pharmacy
Pharmaceutical product development: A quality by design (QbD) approach

Saquib Hasnain,Syed Anees Ahmed,Aisha Khatoon,Mohd Afzal,Mohammed Tahir Ansari,Sidra Khatoon,Mohammad Tabish,Feras M. Al-Marshad,Amit Kumar Nayak,Md Saquib Hasnain

DOI: https://doi.org/10.1016/b978-0-12-820043-8.00017-7

2021-01-01

Abstract:Quality by design (QbD) refers to a scientific approach to product manufacturing that could improve performance, provide regulatory relief and versatility, and deliver substantial business benefits over the product life cycle. It encourages both industry and the FDA to move towards a more research, risk-based, comprehensive, and constructive approach to pharmaceutical production. The International Conference on Harmonization and the United States Food and Drug Administration (USFDA) illustrated the concepts and applications of QbD in pharmaceutical production in their advice to the industry. QbD attributes are discussed in a question-based analysis established by the USFDA Chemistry, Manufacturing and Control Section of Abbreviated New Drug Applications. The QbD principles, when applied, lead to significant product growth, subsequent prompt regulatory approval, reduce the exhaustive burden of validation and substantially reduce post-approval changes. The key elements of QbD viz., target product quality profile, critical quality attributes, risk assessment, design space, control strategy, product lifecycle management and continuous improvement are addressed in order to understand the performance of dosage forms within the design space. The implementation of QbD in the formulation and design of drugs is based on a clear understanding of the sources of uncertainty and the manufacturing process. This analysis underlines the significance of QbD in inculcating a science-based approach to the production of pharmaceutical products.
Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality

Raja Shekhar Nunavath,Madhu Tanya Singh,Anubha Jain,Marjita Chakma,Rajaguru Arivuselvam,Mohamed Sheik Tharik Abdul Azeeze

DOI: https://doi.org/10.1055/a-2185-4916

2023-12-23

Drug Research

Abstract:The pharmaceutical industry has embraced the quality-by-design (QbD) approach as a promising development, formulation and manufacturing strategy. QbD provides a systematic and science-based framework for designing and producing high-quality products, with a particular focus on identifying, assessing and controlling risks throughout the development process. This review aims to assess the benefits of implementing QbD in pharmaceutical processes, evaluate its impact on regulatory compliance and explore its potential to enhance drug product quality. The primary objective of this review is to evaluate the influence of QbD on pharmaceutical development and manufacturing processes. It also seeks to examine the regulatory requirements associated with the implementation of QbD and highlight the advantages of this approach in terms of product quality and cost-effectiveness. Additionally, the review aims to explore the potential of QbD in improving the safety and efficacy of drug products. The QbD approach holds tremendous potential to revolutionize the pharmaceutical industry by optimizing drug development & manufacturing processes, reducing costs and enhancing product quality and consistency. However, implementing QbD requires a comprehensive understanding of the underlying science, as well as strict adherence to regulatory requirements in drug development and manufacturing. In conclusion, by embracing the QbD approach, the pharmaceutical industry can ensure the production of safe, effective and regulation-compliant products while simultaneously improving process efficiency. This strategic shift toward QbD represents a pivotal step in advancing pharmaceutical research and manufacturing capabilities, ultimately benefiting both the industry and more importantly, patients worldwide. Received: 19 July 2023 Accepted: 21 September 2023 Article published online: 22 December 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
Pharmaceutical Product Development: Quality by Design (QbD)

Chintu Valeru

DOI: https://doi.org/10.37022/jpmhs.v7i3.115

2024-08-21

Abstract:A popular modern strategy in pharmaceutical development is called "quality by design," or QBD, which started with established goals including the product's safety and efficacy. Safety and product efficacy are the primary goals of QBD in pharmaceutical development. With QBD, the design itself is emphasized for excellence. QBD was introduced by the Food and Drug Administration in order to comprehend the production process. An overview of the pharmaceutical quality system, quality risk management, and international council for harmonization (ICH) rules for product development is provided in this article in order to preserve product quality. The scientific foundation of QBD, regulatory industry perspectives, and QBD technologies were briefly discussed. There was a focus on excipients, manufacturing process development, container closure systems, and pharmacological substances. The Q9 guidelines for quality risk management, Q10 guidelines for pharmaceutical quality systems, and Q8 guidelines for pharmaceutical development form its basis. In the research and production of pharmaceuticals, it also provides an application of Quality by Design.

Medicine,Business
QUALITY BY DESIGN (QBD): NEW PARAMETER FOR QUALITY IMPROVEMENT & PHARMACEUTICAL DRUG DEVELOPMENT

K. Shah,P. Purohit

Abstract:The purpose of this article is to discuss the concept of pharmaceutical Quality by Design (QbD) and describe how it can be help to ensure pharmaceutical quality & drug development. Quality by design is an essential part of the modern approach to pharmaceutical quality QbD has become the answer to assist both industry and FDA to move towards a more scientific, risk based, holistic and proactive approach to pharmaceutical development. The elements of quality by design are examined and a consistent nomenclature for quality by design, critical quality attribute, critical process parameter, critical material attribute, and control strategy is proposed. The QbD is a systemic approach to pharmaceutical development. It means designing and developing formulations and manufacturing processes to ensure product quality according to requirement Implementation of QbD is enabling transformation of the chemistry, manufacturing, and controls review of Abbreviated New Drug Applications (ANDAs) into a modern, science and risk based pharmaceutical quality assessment. A new approach to drug development could increase efficiencies, provide regulatory relief and flexibility, and offer important business benefits throughout the product’s life cycle.

Medicine,Business,Engineering
Quality by design (QbD) approaches in current pharmaceutical set-up

Vijay Mishra,Sourav Thakur,Akshay Patil,Anshuman Shukla

DOI: https://doi.org/10.1080/17425247.2018.1504768

2018-08-03

Expert Opinion on Drug Delivery

Abstract:INTRODUCTION: Quality by design (QbD) encourages the pharmaceutical industry to use risk management and science-based manufacturing principles to gain process and product understanding and thus assures quality of the product. With the objective to curb the rising costs for development and regulatory barriers to innovation and creativity, QbD is being widely promoted by Food and Drug Administration (FDA) and International Conference on Harmonization (ICH).AREAS COVERED: This review describes the elements, different design and tools of QbD as well as multidimensional applications of QbD ranging from dosage form and method development to meeting latest regulatory requirements.EXPERT OPINION: The understanding of a process is facilitated by proper identification of sources of variation, management of variability by process design, and prediction of product quality attributes using design space. The pharmaceutical industry is rapidly adopting the QbD principles for fabrication of safe, effective and quality products; however, we are still on a journey and the process of gathering all experience and metrics required for connecting and demonstrating QbD benefits to all stakeholders is still in progress. Understanding the formulation and process parameters with the philosophy of QbD will be useful for the optimization of complex drug delivery systems in the near future.

pharmacology & pharmacy
Quality by Design Approaches in Pharmaceutical Development and Solid Dosage Forms Production: A Narrative Overview

Salevendula Sreelekha,K Vinod Kumar,Nawaz Mahammed,T Reshma,G Usha Sree,S Shakir Basha,M Bhuvaneswari

DOI: https://doi.org/10.35516/jjps.v16i4.908

2023-12-25

Jordan Journal of Pharmaceutical Sciences

Abstract:Quality by Design (QbD) is an essential approach to pharmaceutical development and manufacturing that has garnered significant attention in recent years. Quality in services, products, and procedures equates to customer satisfaction. Consequently, it facilitates a transition in the pharmaceutical sector and the Food and Drug Administration (FDA) toward a more scientific, risk-based, comprehensive, and proactive drug development strategy. The pharmaceutical industry is actively seeking new solutions to ensure product quality and efficiency. This paper provides a comprehensive overview of QbD principles and their application in the pharmaceutical industry. The benefits of implementing QbD principles are discussed, encompassing increased efficiency, reduced costs, and improved product quality, safety, and efficacy. As the pharmaceutical industry continues to evolve, QbD will remain a crucial aspect of drug development and manufacturing. This article aims to provide pharmaceutical professionals with a comprehensive understanding of the QbD approach.
Pharmaceutical product development: A quality by design approach

K. Pramod,NaseemA Charoo,ShahidH Ansari,MAbu Tahir,J. Ali

DOI: https://doi.org/10.4103/2230-973X.187350

2016-07-01

International Journal of Pharmaceutical Investigation

Abstract:The application of quality by design (QbD) in pharmaceutical product development is now a thrust area for the regulatory authorities and the pharmaceutical industry. International Conference on Harmonization and United States Food and Drug Administration (USFDA) emphasized the principles and applications of QbD in pharmaceutical development in their guidance for the industry. QbD attributes are addressed in question-based review, developed by USFDA for chemistry, manufacturing, and controls section of abbreviated new drug applications. QbD principles, when implemented, lead to a successful product development, subsequent prompt regulatory approval, reduce exhaustive validation burden, and significantly reduce post-approval changes. The key elements of QbD viz., target product quality profile, critical quality attributes, risk assessments, design space, control strategy, product lifecycle management, and continual improvement are discussed to understand the performance of dosage forms within design space. Design of experiments, risk assessment tools, and process analytical technology are also discussed for their role in QbD. This review underlines the importance of QbD in inculcating science-based approach in pharmaceutical product development.

Computer Science,Medicine,Chemistry,Engineering
Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control

Lawrence X. Yu

DOI: https://doi.org/10.1007/s11095-007-9511-1

IF: 4.58

2008-01-10

Pharmaceutical Research

Abstract:PurposeThe purpose of this paper is to discuss the pharmaceutical Quality by Design (QbD) and describe how it can be used to ensure pharmaceutical quality.Materials and MethodsThe QbD was described and some of its elements identified. Process parameters and quality attributes were identified for each unit operation during manufacture of solid oral dosage forms. The use of QbD was contrasted with the evaluation of product quality by testing alone.ResultsThe QbD is a systemic approach to pharmaceutical development. It means designing and developing formulations and manufacturing processes to ensure predefined product quality. Some of the QbD elements include:Defining target product quality profileDesigning product and manufacturing processesIdentifying critical quality attributes, process parameters, and sources of variabilityControlling manufacturing processes to produce consistent quality over timeConclusionsUsing QbD, pharmaceutical quality is assured by understanding and controlling formulation and manufacturing variables. Product testing confirms the product quality. Implementation of QbD will enable transformation of the chemistry, manufacturing, and controls (CMC) review of abbreviated new drug applications (ANDAs) into a science-based pharmaceutical quality assessment.

pharmacology & pharmacy,chemistry, multidisciplinary
Quality by Design Approach: Progress in Pharmaceutical method Development and Validation

Avinash V. Chavan,R. Gandhimathi

DOI: https://doi.org/10.13005/bpj/2745

2023-09-30

Abstract:Pharmaceutical analysis plays a significant role in pharmaceutical formulation quality assurance and control. Due to the pharmaceutical industries' rapid expansion and the production of pharmaceuticals all over the world, there is a greater need for novel analytical procedures in this sector. Establishing the identification, purity, physical properties, and potency of medications as well as the medication's bioavailability and stability is the goal of analytical method development. A few new drug applications were recently given regulatory flexibility by the Food and Drug Administration for an analytical method based on quality by design. With Quality by design, product design and development are performed methodically. Analytical methodologies have similar opportunities for implementing Quality by design as production procedures do. It consequently enhances formulation design, development efficiency, and capacity. The underpinnings of the QbD approach have been explored in this article due to their use in the creation and validation of analytical procedures. Additionally, a summary of experimental studies reporting the application of the QbD methodology to method development is included.
Bridging the Gap: Quality by Design as a Catalyst for Enhanced Quality Management Systems in Biopharmaceutical Manufacturing

Shivang Saxena,Shubhi Saxena,Diksha,Niraj S Patil,Animesh Ranjan,Amandeep Singh

DOI: https://doi.org/10.2174/0115701638312326240918093333

2024-09-27

Abstract:The document emphasizes the importance of addressing key issues in Quality Management Systems (QMS) to stay competitive and provide high-quality goods and services in a dynamic market. It highlights the need to adopt novel quality management techniques for long-term success. The fundamentals of Quality by Design (QbD) are discussed, tracing back to pioneers like Joseph M. Juran and the Six Sigma concept for effective implementation. QbD is described as a systematic approach focusing on risk management, Quality Target Product Profile (QTPP), and Critical Quality Attributes (CQAs) to create products meeting predetermined quality standards. QbD incorporates quality concepts into the development and production processes. Its goal is to guarantee the quality of the product by determining and managing important factors. Manufacturers can be flexible with it while still adhering to strict quality standards. It signifies a change in the industry's paradigm.
Implementation of Quality by Design in the Program of Safety Re-evaluation of TCM Injections

Liu Li,Qu Haibin

DOI: https://doi.org/10.11842/wst.2013.06.034

2013-01-01

Abstract:It has been widely accepted in modern pharmaceutical industry that quality cannot be tested into products , instead quality should be built-in by design . However , the implementation of Quality by Design ( QbD ) in development , manufacture and supervision of traditional Chinese medicine ( TCM ) still remains to be a challenge . The program of safety re-evaluation of TCM injections provides an opportunity to practice QbD approach in TCM industry . This paper discussed some potential ways that improve the quality of TCM injec-tions base on QbD related tools , including identification of critical quality attributes , critical process parameters and critical material attributes, development of design space and control strategy.
Question-based review for pharmaceutical development: An enhanced quality approach

Ana Simões,Francisco Veiga,Carla Vitorino

DOI: https://doi.org/10.1016/j.ejpb.2023.114174

Abstract:Over the last years, the pharmaceutical industry has faced real challenges regarding quality assurance. In this context, the establishment of more holistic approaches to the pharmaceutical development has been encouraged. The emergence of the Quality by Design (QbD) paradigm as systematic, scientific and risk-based methodology introduced a new concept of pharmaceutical quality. In essence, QbD can be interpreted as a strategy to maximize time and cost savings. An in-depth understanding of the formulation and manufacturing process is demanded to optimize the safety, efficacy and quality of a drug product at all stages of development. This innovative approach streamlines the pharmaceutical Research and Development (R&D) process, provides greater manufacturing flexibility and reduces regulatory burden. To assist in QbD implementation, International Conference on Harmonisation (ICH), U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) organized and launched QbD principles in their guidance for industry, identifying key concepts and tools to design and develop a high-quality drug product. Despite the undeniable advantages of the QbD approach, and the widespread information on QbD regulatory expectations, its full implementation in the pharmaceutical field is still limited. The present review aims to establish a crosswise overview on the current application status of QbD within the framework of the ICH guidelines (ICH Q8(R2) - Q14 and ICH Q2(R2)). Moreover, it outlines the way information gathered from the QbD methodology is being harmonized in Marketing Authorization Applications (MAAs) for European market approval. This work also highlights the challenges that hinder the deployment of the QbD strategy as a standard practice.
[Quality by design approaches for pharmaceutical development and manufacturing of Chinese medicine]

Bing Xu,Xin-Yuan Shi,Zhi-Sheng Wu,Yan-Ling Zhang,Yun Wang,Yan-Jiang Qiao

DOI: https://doi.org/10.19540/j.cnki.cjcmm.20170222.019

Abstract:The pharmaceutical quality was built by design, formed in the manufacturing process and improved during the product's lifecycle. Based on the comprehensive literature review of pharmaceutical quality by design (QbD), the essential ideas and implementation strategies of pharmaceutical QbD were interpreted. Considering the complex nature of Chinese medicine, the "4H" model was innovated and proposed for implementing QbD in pharmaceutical development and industrial manufacture of Chinese medicine product. "4H" corresponds to the acronym of holistic design, holistic information analysis, holistic quality control, and holistic process optimization, which is consistent with the holistic concept of Chinese medicine theory. The holistic design aims at constructing both the quality problem space from the patient requirement and the quality solution space from multidisciplinary knowledge. Holistic information analysis emphasizes understanding the quality pattern of Chinese medicine by integrating and mining multisource data and information at a relatively high level. The batch-to-batch quality consistence and manufacturing system reliability can be realized by comprehensive application of inspective quality control, statistical quality control, predictive quality control and intelligent quality control strategies. Holistic process optimization is to improve the product quality and process capability during the product lifecycle management. The implementation of QbD is useful to eliminate the ecosystem contradictions lying in the pharmaceutical development and manufacturing process of Chinese medicine product, and helps guarantee the cost effectiveness.
Application of the Quality by Design Concept (QbD) in the Development of Hydrogel-Based Drug Delivery Systems

S. Farid Mohseni-Motlagh,Roshanak Dolatabadi,Majid Baniassadi,Mostafa Baghani

DOI: https://doi.org/10.3390/polym15224407

IF: 5

2023-11-15

Polymers

Abstract:Hydrogel-based drug delivery systems are of interest to researchers for many reasons, such as biocompatibility, high diversity, and the possibility of administration from different routes. Despite these advantages, there are challenges, such as controlling the drug release rate and their mechanical properties during the manufacturing of these systems. For this reason, there is a need for the production and development of such drug delivery systems with a scientific strategy. For this reason, the quality by design (QbD) approach is used for the development of drug delivery systems. This approach, by identifying the most effective factors in the manufacturing of pharmaceutical products and controlling them, results in a product with the desired quality with the least number of errors. In this review article, an attempt is made to discuss the application and method of applying this approach in the development of hydrogel-based drug delivery systems. So that for the development and production of these systems, according to the type of drug delivery system, what target characteristics should be considered (QTPP) and what factors, such as material properties (CMA) or process parameters (CPP), should be taken into account to reach the critical quality attributes of the product (CQA).

polymer science
Quality by Design Study of the Direct Analysis in Real Time Mass Spectrometry Response

Lu Wang,Teng Chen,Shanshan Zeng,Haibin Qu

DOI: https://doi.org/10.1007/s13361-013-0779-6

IF: 3.262

2013-01-01

Journal of the American Society for Mass Spectrometry

Abstract:A mass spectrometry method has been developed using the Quality by Design (QbD) principle. Direct analysis in real time mass spectrometry (DART-MS) was adopted to analyze a pharmaceutical preparation. A fishbone diagram for DART-MS and the Plackett-Burman design were utilized to evaluate the impact of a number of factors on the method performance. Multivariate regression and Pareto ranking analysis indicated that the temperature, determined distance, and sampler speed were statistically significant (P < 0.05). Furthermore, the Box-Behnken design combined with response surface analysis was then employed to study the relationships between these three factors and the quality of the DART-MS analysis. The analytical design space of DART-MS was thus constructed and its robustness was validated. In this presented approach, method performance was mathematically described as a composite desirability function of the critical quality attributes (CQAs). Two terms of method validation, including analytical repeatability and method robustness, were carried out at an operating work point. Finally, the validated method was successfully applied to the pharmaceutical quality assurance in different manufacturing batches. These results revealed that the QbD concept was practical in DART-MS method development. Meanwhile, the determined quality was controlled by the analytical design space. This presented strategy provided a tutorial to the development of a robust QbD-compliant mass spectrometry method for industrial quality control.
Mastering Quality: Uniting Risk Assessment With Quality by Design (QbD) Principles for Pharmaceutical Excellence

Abdul M Kaleem,Jebastin Koilpillai,Damodharan Narayanasamy

DOI: https://doi.org/10.7759/cureus.68215

2024-08-30

Cureus

Abstract:The aim of this article is to present ideas and tools of risk assessment that can be implemented to overcome various pharmaceutical quality challenges. These elements cover the development, production, distribution, inspection, and reporting of review procedures for drug substances, drug products, and biological products at every stage of their lifecycle. In light of the constant requirement to ensure the drug's efficacy, safety, and quality, the pharmaceutical sector is always evolving. A key strategy for attaining pharmaceutical excellence in this dynamic environment is incorporating novel methods like quality by design (QbD) and risk assessment. Risk assessment is a methodical strategy to locate, assess, and minimize any risks in the manufacturing and development of pharmaceuticals. On the other hand, QbD principles place more emphasis on end-product testing and place it in the context of designing quality into the product from the beginning. The major goal of this paper is to address and examine the integration of risk assessment approaches with the QbD principle workflow to ensure pharmaceutical quality. Recent articles on how risk assessment has been used in pharmaceuticals were evaluated. To provide a useful overview, the various assessment methodologies have been highlighted, emphasizing their benefits and drawbacks.
Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD)

Isa Martins Fukuda,Camila Francini Fidelis Pinto,Camila dos Santos Moreira,Alessandro Morais Saviano,Felipe Rebello Lourenço,Camila dos Santos Moreira

DOI: https://doi.org/10.1590/s2175-97902018000001006

2018-11-08

Brazilian Journal of Pharmaceutical Sciences

Abstract:According to Quality by Design (QbD) concept, quality should be built into product/method during pharmaceutical/analytical development. Usually, there are many input factors that may affect quality of product and methods. Recently, Design of Experiments (DoE) have been widely used to understand the effects of multidimensional and interactions of input factors on the output responses of pharmaceutical products and analytical methods. This paper provides theoretical and practical considerations for implementation of Design of Experiments (DoE) in pharmaceutical and/or analytical Quality by Design (QbD). This review illustrates the principles and applications of the most common screening designs, such as two-level full factorial, fractionate factorial, and Plackett-Burman designs; and optimization designs, such as three-level full factorial, central composite designs (CCD), and Box-Behnken designs. In addition, the main aspects related to multiple regression model adjustment were discussed, including the analysis of variance (ANOVA), regression significance, residuals analysis, determination coefficients (R2, R2-adj, and R2-pred), and lack-of-fit of regression model. Therefore, DoE was presented in detail since it is the main component of pharmaceutical and analytical QbD.

pharmacology & pharmacy

Aspects and Implementation of Pharmaceutical Quality by Design

Quality-by-design in pharmaceutical development: From current perspectives to practical applications

Quality by Design (QbD) in pharmaceutical development: A comprehensive review

Quality By Design (QbD): A Comprehensive Understanding and Implementation In Pharmaceuticals Development

Pharmaceutical product development: A quality by design (QbD) approach

Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality

Pharmaceutical Product Development: Quality by Design (QbD)

QUALITY BY DESIGN (QBD): NEW PARAMETER FOR QUALITY IMPROVEMENT & PHARMACEUTICAL DRUG DEVELOPMENT

Quality by design (QbD) approaches in current pharmaceutical set-up

Quality by Design Approaches in Pharmaceutical Development and Solid Dosage Forms Production: A Narrative Overview

Pharmaceutical product development: A quality by design approach

Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control

Quality by Design Approach: Progress in Pharmaceutical method Development and Validation

Bridging the Gap: Quality by Design as a Catalyst for Enhanced Quality Management Systems in Biopharmaceutical Manufacturing

Implementation of Quality by Design in the Program of Safety Re-evaluation of TCM Injections

Question-based review for pharmaceutical development: An enhanced quality approach

[Quality by design approaches for pharmaceutical development and manufacturing of Chinese medicine]

Application of the Quality by Design Concept (QbD) in the Development of Hydrogel-Based Drug Delivery Systems

Quality by Design Study of the Direct Analysis in Real Time Mass Spectrometry Response

Mastering Quality: Uniting Risk Assessment With Quality by Design (QbD) Principles for Pharmaceutical Excellence

Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD)